NEW HAVEN, Conn., June 3, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF)...
Read More Details
Finally We wish PressBee provided you with enough information of ( Trevi Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock )
Also on site :